keyword
MENU ▼
Read by QxMD icon Read
search

Antidepressants schizophrenia

keyword
https://www.readbyqxmd.com/read/28087837/off-target-effects-of-neuroleptics-and-antidepressants-on-saccharomyces-cerevisiae
#1
M Caldara, S Graziano, M Gullì, S Cadonici, Nelson Marmiroli
Over the past years, the use of antidepressants and neuroleptics has steadily increased. Although incredibly useful to treat disorders like depression, schizophrenia, epilepsy, or mental retardation, these drugs display many side effects. Toxicogenomic studies aim to limit this problem by trying to identify cellular targets and off-targets of medical compounds. The baker yeast Saccharomyces cerevisiae has been shown to be a key player in this approach, as it represents an incredible toolbox for the dissection of complex biological processes...
January 13, 2017: Toxicological Sciences: An Official Journal of the Society of Toxicology
https://www.readbyqxmd.com/read/28049075/abnormal-brain-oscillations-persist-after-recovery-from-bipolar-depression
#2
P Canali, S Casarotto, M Rosanova, G Sferrazza-Papa, A G Casali, O Gosseries, M Massimini, E Smeraldi, C Colombo, F Benedetti
When directly perturbed in healthy subjects, premotor cortical areas generate electrical oscillations in the beta range (20-40Hz). In schizophrenia, major depressive disorder and bipolar disorder (BD), these oscillations are markedly reduced, in terms of amplitude and frequency. However, it still remains unclear whether these abnormalities can be modulated over time, or if they can be still observed after treatment. Here, we employed transcranial magnetic stimulation (TMS) combined with EEG to assess the frontal oscillatory activity in eighteen BD patients before/after antidepressant treatments (sleep deprivation and light therapy), relative to nine healthy controls...
December 27, 2016: European Psychiatry: the Journal of the Association of European Psychiatrists
https://www.readbyqxmd.com/read/28011708/more-actions-needed-to-reach-a-consensus-on-adjunctive-antidepressant-therapy-for-negative-symptoms-of-schizophrenia
#3
Shahin Akhondzadeh, Ehsan Moazen-Zadeh
No abstract text is available yet for this article.
December 23, 2016: Evidence-based Mental Health
https://www.readbyqxmd.com/read/27984260/persistent-interictal-musical-hallucination-in-a-patient-with-mesial-temporal-sclerosis-related-epilepsy-first-case-report-and-etiopathological-hypothesis
#4
Paolo Borelli, Marcella Vedovello, Massimiliano Braga, Massimo Pederzoli, Sandro Beretta
Musical hallucination is a disorder of complex sound processing of instrumental music, songs, choirs, chants, etc. The underlying pathologies include moderate to severe acquired hearing loss (the auditory equivalent of Charles Bonnet syndrome), psychiatric illnesses (depression, schizophrenia), drug intoxication (benzodiazepines, salicylate, pentoxifylline, propranolol), traumatic lesions along the acoustic pathways, and epilepsy. The hallucinations are most likely to begin late in life; 70% of patients are women...
December 2016: Cognitive and Behavioral Neurology: Official Journal of the Society for Behavioral and Cognitive Neurology
https://www.readbyqxmd.com/read/27932945/monoaminergic-and-histaminergic-strategies-and-treatments-in-brain-diseases
#5
REVIEW
Giuseppe Di Giovanni, Dubravka Svob Strac, Montse Sole, Mercedes Unzeta, Keith F Tipton, Dorotea Mück-Šeler, Irene Bolea, Laura Della Corte, Matea Nikolac Perkovic, Nela Pivac, Ilse J Smolders, Anna Stasiak, Wieslawa A Fogel, Philippe De Deurwaerdère
The monoaminergic systems are the target of several drugs for the treatment of mood, motor and cognitive disorders as well as neurological conditions. In most cases, advances have occurred through serendipity, except for Parkinson's disease where the pathophysiology led almost immediately to the introduction of dopamine restoring agents. Extensive neuropharmacological studies first showed that the primary target of antipsychotics, antidepressants, and anxiolytic drugs were specific components of the monoaminergic systems...
2016: Frontiers in Neuroscience
https://www.readbyqxmd.com/read/27922594/cacna1c-in-the-prefrontal-cortex-regulates-depression-related-behaviors-via-redd1
#6
Zeeba D Kabir, Anni S Lee, Caitlin E Burgdorf, Delaney Fischer, Aditi M Rajadhyaksha, Ethan Mok, Bryant Rizzo, Richard C Rice, Kamalpreet Singh, Kristie T Ota, Danielle M Gerhard, Kathryn C Schierberl, Michael Glass, Ronald S Duman, Anjali M Rajadhyaksha
The CACNA1C gene that encodes the L-type Ca(2+) channel (LTCC) Cav1.2 subunit has emerged as a candidate risk gene for multiple neuropsychiatric disorders including bipolar disorder, major depressive disorder and schizophrenia, all marked with depression-related symptoms. Although cacna1c heterozygous (HET) mice have been previously reported to exhibit an antidepressant-like phenotype, the molecular and circuit-level dysfunction remains unknown. Here we report that viral vector-mediated deletion of cacna1c in the adult prefrontal cortex (PFC) of mice recapitulates the antidepressant-like effect observed in cacna1c HET mice using the sucrose preference test (SPT), the forced swim test (FST), and the tail suspension test (TST)...
December 6, 2016: Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/27889833/factors-associated-with-expression-of-extrapyramidal-symptoms-in-users-of-atypical-antipsychotics
#7
Susana Barbosa Ribeiro, Aurigena Antunes de Araújo, Caroline Addison Xavier Medeiros, Katarina Melo Chaves, Maria do Socorro Costa Feitosa Alves, Antonio Gouveia Oliveira, Rand Randall Martins
PURPOSE: The aim of this study was to investigate factors associated with the occurrence of extrapyramidal symptoms (EPS) in users of second-generation antipsychotics (SGA). METHODS: Observational cross-sectional study based on a random sample of subjects from three outpatient clinics. Inclusion criteria were age between 18 and 65 years, of both genders, with a diagnosis of schizophrenia and under the use of a single SGA agent. Subjects who had received i.m. long-acting antipsychotics in the past were excluded...
November 26, 2016: European Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/27872261/comorbid-diabetes-and-depression-in-a-national-sample-of-adults-with-psychosis
#8
Debra L Foley, Andrew Mackinnon, Vera A Morgan, David J Castle, Anna Waterreus, Cherrie A Galletly
OBJECTIVE: People with psychosis have an elevated risk of depression and diabetes but no large-scale study has characterized their relationship. We aimed to assess this association and to evaluate possible explanatory factors. METHODS: Analysis of cross-sectional data from a national sample of 1155 people with psychosis who gave a fasting blood sample and could be tested for diabetes mellitus. The association between current diabetes mellitus and current depression was estimated using logistic regression, adjusted for age, sex and current psychotropic medication...
November 21, 2016: Schizophrenia Bulletin
https://www.readbyqxmd.com/read/27855437/the-relevance-of-negative-symptoms-in-schizophrenia-and-how-to-treat-them-with-psychopharmaceuticals
#9
Hans-Jürgen Möller
Negative symptoms are highly prevalent in the acute episode and long-term course of schizophrenia. They are often persistent and tend to chronicity. They have an important negative impact on different dimensions of outcome and therefore require careful diagnosis and treatment. However, the evidence for the available psychopharmacological treatments is still not satisfactory and further research is needed. Antipsychotics, especially some second-generation antipsychotics, are the primary treatment of choice, particularly for negative symptoms in the acute episode...
December 2016: Psychiatria Danubina
https://www.readbyqxmd.com/read/27846049/agomelatine-for-the-treatment-of-major-depressive-episodes-in-schizophrenia-spectrum-disorders-an-open-prospective-proof-of-concept-study
#10
Susanne Englisch, Hanna Sophie Jung, Antje Lewien, Anna Becker, Ulrike Nowak, Hanna Braun, Jascha Thiem, Sarah Eisenacher, Andreas Meyer-Lindenberg, Mathias Zink
BACKGROUND: Depressive episodes in schizophrenia constitute a major clinical problem, and treatment success is often limited by treatment-emergent side effects. Agomelatine, an agonist at melatonergic MT1/MT2 receptors and 5-HT2C receptor antagonist, is a new antidepressant with a novel mode of action which constitutes a potential therapeutic option for depression in schizophrenia. METHODS: Twenty-seven patients with lifetime diagnoses within the schizophrenia spectrum and comorbid depression were treated with agomelatine in addition to stable doses of antipsychotic agents...
October 29, 2016: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/27845315/-agomelatine-valdoxan-in-treatment-of-endogenous-depression-in-day-patient-department
#11
E V Chernova, O V Kozhechkina, A Yu Ter-Israelyan, V E Medvedev
AIM: Naturalistic psychopharmacological study of efficacy and tolerability of agomelatine (valdoxan) in treatment of endogenous depressions (in the framework of schizophrenia, schizoaffective and bipolar disorder) in day patient department. MATERIAL AND METHODS: Study sample consisted of 37 patient (59.4% female, mean age 41.6±3.7 years). RESULTS AND CONCLUSION: CDS total score significantly reduced after 8 weeks of treatment 44.9% compared to baseline (р<0...
2016: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
https://www.readbyqxmd.com/read/27827340/no-association-between-current-depression-and-latent-toxoplasmosis-in-adults
#12
Shawn D Gale, Andrew N Berrett, Bruce Brown, Lance D Erickson, Dawson W Hedges
Changes in behaviour and cognition have been associated with latent infection from the apicomplexan protozoan Toxoplasma gondii (Nicolle et Manceaux, 1908) in both animal and human studies. Further, neuropsychiatric disorders such as schizophrenia have also been associated with latent toxoplasmosis. Previously, we found no association between T. gondii immunoglobulin G antibody (IgG) seropositivity and depression in human adults between the ages of 20 and 39 years (n = 1 846) in a sample representative of the United States collected by the Centers for Disease Control as part of a National Health and Nutrition Examination Survey (NHANES) from three datasets collected between 1999-2004...
September 26, 2016: Folia Parasitologica
https://www.readbyqxmd.com/read/27825780/demographic-and-clinical-differences-between-early-and-late-onset-bipolar-disorders-in-a-multicenter-study-in-china
#13
Ling Zhang, Hai-Chen Yang, Xiu-Feng Xu, Yi-Ru Fang, Xin Yu, Qing-Rong Tan, Hui-Chun Li, Gabor S Ungvari, Chee H Ng, Gang Wang, Yu-Tao Xiang
Little is known about the demographic and clinical differences between early-onset (EOB) and late-onset bipolar disorders (LOB) in Chinese patients. This multi-center study examined the demographic and clinical characteristics of EOB (≤21 years) and LOB (>21 years) in China. A consecutively recruited sample of 555 patients with bipolar disorder (BD) from 7 psychiatric hospitals and general hospital psychiatric units across China was examined. Patients' demographic and clinical characteristics were collected using a standardized protocol and data collection procedure...
December 30, 2016: Psychiatry Research
https://www.readbyqxmd.com/read/27805978/agomelatine-for-the-treatment-of-major-depressive-episodes-in-schizophrenia-spectrum-disorders-an-open-prospective-proof-of-concept-study
#14
Susanne Englisch, Hanna Sophie Jung, Antje Lewien, Anna Becker, Ulrike Nowak, Hanna Braun, Jascha Thiem, Sarah Eisenacher, Andreas Meyer-Lindenberg, Mathias Zink
BACKGROUND: Depressive episodes in schizophrenia constitute a major clinical problem, and treatment success is often limited by treatment-emergent side effects. Agomelatine, an agonist at melatonergic MT1/MT2 receptors and 5-HT2C receptor antagonist, is a new antidepressant with a novel mode of action which constitutes a potential therapeutic option for depression in schizophrenia. METHODS: Twenty-seven patients with lifetime diagnoses within the schizophrenia spectrum and comorbid depression were treated with agomelatine in addition to stable doses of antipsychotic agents...
December 2016: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/27796754/ketamine-self-administration-reduces-the-homeostasis-of-the-glutamate-synapse-in-the-rat-brain
#15
Lucia Caffino, Alessandro Piva, Giuseppe Giannotti, Marzia Di Chio, Francesca Mottarlini, Marco Venniro, David T Yew, Cristiano Chiamulera, Fabio Fumagalli
Ketamine is a non-competitive antagonist of the NMDA glutamate receptor with psychotomimetic and reinforcing properties, although recent work has pointed out its antidepressant action following acute exposure. Our aim was to investigate the expression of crucial components of the glutamate synapse following chronic ketamine self-administration (S/A), focusing our attention on medial prefrontal cortex (mPFC) and hippocampus (Hip), two brain regions involved in compulsive drug-seeking and drug-related cognitive disorders...
October 29, 2016: Molecular Neurobiology
https://www.readbyqxmd.com/read/27774073/effects-of-music-therapy-on-drug-therapy-of-adult-psychiatric-outpatients-a-pilot-randomized-controlled-study
#16
Mario Degli Stefani, Michele Biasutti
Objective: Framed in the patients' engagement perspective, the current study aims to determine the effects of group music therapy in addition to drug care in comparison with drug care in addition to other non-expressive group activities in the treatment of psychiatric outpatients. Method: Participants (n = 27) with ICD-10 diagnoses of F20 (schizophrenia), F25 (schizoaffective disorders), F31 (bipolar affective disorder), F32 (depressive episode), and F60 (specific personality disorders) were randomized to receive group music therapy plus standard care (48 weekly sessions of 2 h) or standard care only...
2016: Frontiers in Psychology
https://www.readbyqxmd.com/read/27757131/decreased-plasma-bdnf-levels-of-patients-with-somatization-disorder
#17
Nam-In Kang, Jong-Il Park, Yong-Ku Kim, Jong-Chul Yang
OBJECTIVE: Brain-derived neurotrophic factor (BDNF), one of the most abundant and important neurotrophins, is known to be involved in the development, survival, maintenance, and plasticity of neurons in the nervous system. Some studies have suggested that BDNF may play a role in the pathophysiology of several psychiatric illnesses such as depression and schizophrenia. Similarly, it is likely that the alteration of BDNF may be associated with the neuro-modulation that contributes to the development of somatization disorder...
September 2016: Psychiatry Investigation
https://www.readbyqxmd.com/read/27701952/add-on-mirtazapine-improves-orgasmic-functioning-in-patients-with-schizophrenia-treated-with-first-generation-antipsychotics
#18
Viacheslav Terevnikov, Jan-Henry Stenberg, Jari Tiihonen, Mark Burkin, Grigori Joffe
AIM: Sexual dysfunction, common in schizophrenia, may be further exaggerated by antipsychotics, especially those of First Generation (FGAs), and antidepressants, such as Selective Serotonin Reuptake Inhibitors (SSRs). Mirtazapine, an antidepressant characterized by its different action mechanism compared with that of the majority of other antidepressants, may improve SSRI-induced sexual dysfunction in patients with depression. It is unknown, however, whether mirtazapine improves sexual functioning in schizophrenia...
January 2017: Nordic Journal of Psychiatry
https://www.readbyqxmd.com/read/27658832/treatment-patterns-of-schizophrenia-based-on-the-data-from-seven-central-and-eastern-european-countries
#19
Monika Szkultecka-Dębek, Katarzyna Miernik, Jarosław Stelmachowski, Miro Jakovljević, Vlado Jukić, Kaire Aadamsoo, Sven Janno, István Bitter, Judit Tolna, Marek Jarema, Slobodan Jankovic, Jan Pecenak, Livia Vavrusova, Rok Tavčar, Jacek Walczak, Darren Talbot, Joanna Augustyńska
OBJECTIVE: The aim is to analyze how schizophrenia is pharmacologically treated in seven CEE countries: Croatia, Estonia, Hungary, Poland, Serbia, Slovakia and Slovenia. METHODS: Psychiatrists from selected centers in each of participating countries were asked to complete a pre-defined questionnaire on their current clinical practice. Information on protocols and resource utilization in schizophrenia treatment was included and derived from randomly selected patient medical records...
September 2016: Psychiatria Danubina
https://www.readbyqxmd.com/read/27638627/the-risk-of-thromboembolism-in-users-of-antidepressants-and-antipsychotics
#20
Kasper Adelborg, Jens Sundbøll, Poul Videbech, Erik L Grove
Arterial and venous thromboembolism are common causes of morbidity and mortality in the Western world. Mental disorders are also highly prevalent with a lifetime risk of experiencing any psychiatric disease ranging between 32 % and 37 %. Depression and schizophrenia may increase the risk of thromboembolism through genetic, behavioral, and biological mechanisms. Treatment of psychiatric patients with psychotropic drugs is imperative to improve quality of life and to reduce morbidity and mortality. However, studies have shown that psychotropic drugs themselves may modify the risk of arterial and venous thromboembolism, which should be taken into consideration when using these drugs in clinical practice...
September 17, 2016: Advances in Experimental Medicine and Biology
keyword
keyword
51990
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"